Global Alzheimer's Disease Drug 麻豆原创 Research Report 2025

Publication ID:

PB505250369

Publication Date:

May 6, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Alzheimer's Disease Drug was valued at US$ 3727 million in the year 2024 and is projected to reach a revised size of US$ 4130 million by 2031, growing at a CAGR of 1.5% during the forecast period.
Alzheimer"s disease (AD), also referred to simply as Alzheimer"s, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The major players in global Alzheimer鈥檚 Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Alzheimer's Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alzheimer's Disease Drug.
The Alzheimer's Disease Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Alzheimer's Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alzheimer's Disease Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Segment by Type
Donepezil
Memantine
Rivastigmine
Others
Segment by Application
Early to Moderate Stages
Moderate to Severe Stages
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Alzheimer's Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Alzheimer's Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Alzheimer's Disease Drug 麻豆原创 Overview
1.1 Product Definition
1.2 Alzheimer's Disease Drug by Type
1.2.1 Global Alzheimer's Disease Drug 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Donepezil
1.2.3 Memantine
1.2.4 Rivastigmine
1.2.5 Others
1.3 Alzheimer's Disease Drug by Application
1.3.1 Global Alzheimer's Disease Drug 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Early to Moderate Stages
1.3.3 Moderate to Severe Stages
1.4 Global Alzheimer's Disease Drug 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Alzheimer's Disease Drug Revenue 2020-2031
1.4.2 Global Alzheimer's Disease Drug Sales 2020-2031
1.4.3 Global Alzheimer's Disease Drug 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Alzheimer's Disease Drug 麻豆原创 Competition by Manufacturers
2.1 Global Alzheimer's Disease Drug Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Alzheimer's Disease Drug Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Alzheimer's Disease Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Alzheimer's Disease Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Alzheimer's Disease Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Alzheimer's Disease Drug, Product Type & Application
2.7 Global Key Manufacturers of Alzheimer's Disease Drug, Date of Enter into This Industry
2.8 Global Alzheimer's Disease Drug 麻豆原创 Competitive Situation and Trends
2.8.1 Global Alzheimer's Disease Drug 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Alzheimer's Disease Drug Players 麻豆原创 Share by Revenue
2.8.3 Global Alzheimer's Disease Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Alzheimer's Disease Drug 麻豆原创 Scenario by Region
3.1 Global Alzheimer's Disease Drug 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Alzheimer's Disease Drug Sales by Region: 2020-2031
3.2.1 Global Alzheimer's Disease Drug Sales by Region: 2020-2025
3.2.2 Global Alzheimer's Disease Drug Sales by Region: 2026-2031
3.3 Global Alzheimer's Disease Drug Revenue by Region: 2020-2031
3.3.1 Global Alzheimer's Disease Drug Revenue by Region: 2020-2025
3.3.2 Global Alzheimer's Disease Drug Revenue by Region: 2026-2031
3.4 North America Alzheimer's Disease Drug 麻豆原创 Facts & Figures by Country
3.4.1 North America Alzheimer's Disease Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Alzheimer's Disease Drug Sales by Country (2020-2031)
3.4.3 North America Alzheimer's Disease Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Alzheimer's Disease Drug 麻豆原创 Facts & Figures by Country
3.5.1 Europe Alzheimer's Disease Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Alzheimer's Disease Drug Sales by Country (2020-2031)
3.5.3 Europe Alzheimer's Disease Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Alzheimer's Disease Drug 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Alzheimer's Disease Drug 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Alzheimer's Disease Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Alzheimer's Disease Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Alzheimer's Disease Drug 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Alzheimer's Disease Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Alzheimer's Disease Drug Sales by Country (2020-2031)
3.7.3 Latin America Alzheimer's Disease Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Alzheimer's Disease Drug 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Alzheimer's Disease Drug 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Alzheimer's Disease Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Alzheimer's Disease Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Alzheimer's Disease Drug Sales by Type (2020-2031)
4.1.1 Global Alzheimer's Disease Drug Sales by Type (2020-2025)
4.1.2 Global Alzheimer's Disease Drug Sales by Type (2026-2031)
4.1.3 Global Alzheimer's Disease Drug Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Alzheimer's Disease Drug Revenue by Type (2020-2031)
4.2.1 Global Alzheimer's Disease Drug Revenue by Type (2020-2025)
4.2.2 Global Alzheimer's Disease Drug Revenue by Type (2026-2031)
4.2.3 Global Alzheimer's Disease Drug Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Alzheimer's Disease Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Alzheimer's Disease Drug Sales by Application (2020-2031)
5.1.1 Global Alzheimer's Disease Drug Sales by Application (2020-2025)
5.1.2 Global Alzheimer's Disease Drug Sales by Application (2026-2031)
5.1.3 Global Alzheimer's Disease Drug Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Alzheimer's Disease Drug Revenue by Application (2020-2031)
5.2.1 Global Alzheimer's Disease Drug Revenue by Application (2020-2025)
5.2.2 Global Alzheimer's Disease Drug Revenue by Application (2026-2031)
5.2.3 Global Alzheimer's Disease Drug Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Alzheimer's Disease Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Company Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Allergan Alzheimer's Disease Drug Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 Eisai
6.2.1 Eisai Company Information
6.2.2 Eisai Description and Business Overview
6.2.3 Eisai Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eisai Alzheimer's Disease Drug Product Portfolio
6.2.5 Eisai Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Alzheimer's Disease Drug Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Daiichi Sankyo
6.4.1 Daiichi Sankyo Company Information
6.4.2 Daiichi Sankyo Description and Business Overview
6.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Daiichi Sankyo Alzheimer's Disease Drug Product Portfolio
6.4.5 Daiichi Sankyo Recent Developments/Updates
6.5 Merz Pharma
6.5.1 Merz Pharma Company Information
6.5.2 Merz Pharma Description and Business Overview
6.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merz Pharma Alzheimer's Disease Drug Product Portfolio
6.5.5 Merz Pharma Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Company Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Pfizer Alzheimer's Disease Drug Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Johnson & Johnson
6.7.1 Johnson & Johnson Company Information
6.7.2 Johnson & Johnson Description and Business Overview
6.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Johnson & Johnson Alzheimer's Disease Drug Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Lundbeck
6.8.1 Lundbeck Company Information
6.8.2 Lundbeck Description and Business Overview
6.8.3 Lundbeck Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Lundbeck Alzheimer's Disease Drug Product Portfolio
6.8.5 Lundbeck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Alzheimer's Disease Drug Industry Chain Analysis
7.2 Alzheimer's Disease Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Alzheimer's Disease Drug Production Mode & Process Analysis
7.4 Alzheimer's Disease Drug Sales and 麻豆原创ing
7.4.1 Alzheimer's Disease Drug Sales Channels
7.4.2 Alzheimer's Disease Drug Distributors
7.5 Alzheimer's Disease Drug Customer Analysis
8 Alzheimer's Disease Drug 麻豆原创 Dynamics
8.1 Alzheimer's Disease Drug Industry Trends
8.2 Alzheimer's Disease Drug 麻豆原创 Drivers
8.3 Alzheimer's Disease Drug 麻豆原创 Challenges
8.4 Alzheimer's Disease Drug 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.